Summary
Desmopressin (1-desamino-8-D-arginine vasopressin), an established hemostatic agent for the treatment of bleeding in mild hemophilia A, von Willebrand's disease, or platelet disorders, has mostly been given parenterally as intravenous or subcutaneous injections. Intranasal administration by spray has been shown to yield significant and highly reproducible increases in the plasma concentrations of factor VIII and von Willebrand factor and platelet adhesiveness, and to be suitable for self-administration at home, as it is easy to handle and does not involve the use of needles. This paper presents data from a questionnaire answered by 78 patients with mild hemophilia A, von Willebrand's disease, or platelet disorders, who had used the spray at home to treat bleeding symptoms. The patients experienced decreased blood loss and shortened duration of epistaxis, menorrhagia, tissue bleeding, and bleeding in connection with minor surgery or tooth extraction. The use of factor VIII concentrates was diminished, as were the number of visits to outpatient care and absence from school or work.
Similar content being viewed by others
References
Cash JD, Gader AMA, Da Costa J (1974) The release of plasminogen activator and factor VIII by LVP, AVP, DDAVP, AT III and OT in man. Br J Haematol 27: 363–364
Harris AS, Nilsson IM, Wagner ZG, Alkner U (1986) Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin. J Pharm Sci 75: 1085–1088
Kentro TB, Lottenberg R, Kitchens CS (1987) Clinical efficacy of desmopressin acetate for hemostatic control in patients with primary platelet disorders undergoing surgery. Am J Hematol 24: 215–219
Kobrinsky NL, Israels ED, Gerrard JM, et al. (1984) Shortening of the bleeding time by 1-deamino-8-D arginine vasopressin in various bleeding disorders. Lancet 1: 1145–1148
Köhler M, Hellstern P, Miyashita C, von Blohm G, Wenzel E (1986) Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginme vasopressin (DDAVP). Thromb Haemost 55: 108–111
Köhler M, Hellstern P, Tarrach H, Rambauer R, Wenzel E, Jutzler GA (1989) Subcutaneous injection of desmopressin (DDAVP): evaluation of a new, more concentrated preparation. Haemostasis 1: 38–44
Lethagen S, Nilsson IM (1992) DDAVP-induced enhancement of platelet retention. Its dependence on platelet-von Willebrand factor and the platelet receptor GP IIb/IIIa. Eur J Haematol 49: 7–13
Lethagen S, Harris AS, Sjörin E, Nilsson IM (1987) Intranasal and intravenous administration of desmopressin: effect on FVIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 58: 1033–1036
Lethagen S, Harris AS, Nilsson IM (1990) Intranasal desmopressin (DDAVP) by spray in mild haemophilia A and von Willebrand's disease type I. Blut 60: 187–191
Mannucci PM, Åberg M, Nilsson IM, Robertsson B (1975) Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 30: 81–93
Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) 1-Deamino-8-D-arginme vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet 1: 869–872
Mannucci PM, Canciani MT, Rota L, Donovan BS (1981) Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects, and patients with haemophilia A and von Willebrand's disease. Br J Haematol 47: 283–293
Mannucci PM, Vicente V, Vianello L, et al. (1986) Controlled trial of desmopressin in liver cirrhosis and other conditions associated with prolonged bleeding time. Blood 67: 1148–1153
Nilsson IM, Felding P, Timberg L, Jonsson S, Harris AS (1986) Clinical experience with (DDAVP). In: Ciavarella NL, Ruggeri Z, Zimmerman TS (eds) Factor VIII/von Willebrand factor. Biological and clinical advances. Proceedings of Bari Intl Conference. Wichtig, Milano, pp 63–80
Nilsson IM, Lethagen S (1991) Current status of DDAVP formulations and their use. In: Lusher JM, Kessler CM (eds) Hemophilia and von Willebrand's disease in the 1990s. Elsevier Science, Amsterdam, pp 443–453
Rose EH, Aledort LM(1991) Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 114: 563–568
Warrier AI, Lusher JM (1983) DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease. J Pediatr 102: 228–233
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lethagen, S., Tennvall, G.R. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders: Effect on bleeding symptoms and socioeconomic factors. Ann Hematol 66, 257–260 (1993). https://doi.org/10.1007/BF01738476
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01738476